Last reviewed · How we verify
Antidepressant Therapy
Antidepressant therapy works by modulating neurotransmitter levels in the brain to alleviate symptoms of depression.
Antidepressant therapy works by modulating neurotransmitter levels in the brain to alleviate symptoms of depression. Used for Major depressive disorder, Generalized anxiety disorder (select agents), Obsessive-compulsive disorder (select agents).
At a glance
| Generic name | Antidepressant Therapy |
|---|---|
| Also known as | Fluoxetine, Amitriptyline |
| Sponsor | RAND |
| Drug class | Antidepressant (class varies by specific agent) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Antidepressants typically increase the availability of neurotransmitters such as serotonin, norepinephrine, or dopamine in synaptic spaces by inhibiting their reuptake or through other mechanisms. This enhanced neurotransmitter signaling helps restore mood regulation and alleviates depressive symptoms. The specific mechanism varies by drug class (SSRIs, SNRIs, tricyclics, MAOIs, etc.).
Approved indications
- Major depressive disorder
- Generalized anxiety disorder (select agents)
- Obsessive-compulsive disorder (select agents)
- Post-traumatic stress disorder (select agents)
Common side effects
- Nausea
- Headache
- Sexual dysfunction
- Insomnia or somnolence
- Weight gain
- Dizziness
Key clinical trials
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- Minocycline as Adjunctive Treatment for Treatment Resistant Depression (PHASE3)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Pharmacogenetic-Guided Antidepressant Treatment in Depression (NA)
- Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder (PHASE2)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Psilocybin for Treatment-Resistant Depression in Autism (PHASE1)
- A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antidepressant Therapy CI brief — competitive landscape report
- Antidepressant Therapy updates RSS · CI watch RSS
- RAND portfolio CI